vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Sprout Social, Inc. (SPT). Click either name above to swap in a different company.

Sprout Social, Inc. is the larger business by last-quarter revenue ($120.9M vs $77.6M, roughly 1.6× Bioceres Crop Solutions Corp.). On growth, Sprout Social, Inc. posted the faster year-over-year revenue change (12.9% vs -16.8%). Over the past eight quarters, Sprout Social, Inc.'s revenue compounded faster (11.8% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Sprout Social, Inc. is a technology company that runs a social media management platform. A public company headquartered in Chicago, it was founded in 2010 by Justyn Howard, Aaron Rankin, Gil Lara, and Peter Soung.

BIOX vs SPT — Head-to-Head

Bigger by revenue
SPT
SPT
1.6× larger
SPT
$120.9M
$77.6M
BIOX
Growing faster (revenue YoY)
SPT
SPT
+29.7% gap
SPT
12.9%
-16.8%
BIOX
Faster 2-yr revenue CAGR
SPT
SPT
Annualised
SPT
11.8%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
SPT
SPT
Revenue
$77.6M
$120.9M
Net Profit
$-7.4M
Gross Margin
46.8%
77.6%
Operating Margin
9.3%
-9.0%
Net Margin
-9.6%
Revenue YoY
-16.8%
12.9%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
SPT
SPT
Q4 25
$120.9M
Q3 25
$77.6M
$115.6M
Q2 25
$111.8M
Q1 25
$60.6M
$109.3M
Q4 24
$98.8M
$107.1M
Q3 24
$93.3M
$102.6M
Q2 24
$99.4M
Q1 24
$84.0M
$96.8M
Net Profit
BIOX
BIOX
SPT
SPT
Q4 25
Q3 25
$-7.4M
$-9.4M
Q2 25
$-12.0M
Q1 25
$-1.6M
$-11.2M
Q4 24
$605.2K
Q3 24
$-6.2M
$-17.1M
Q2 24
$-16.9M
Q1 24
$9.8M
$-13.6M
Gross Margin
BIOX
BIOX
SPT
SPT
Q4 25
77.6%
Q3 25
46.8%
77.7%
Q2 25
77.7%
Q1 25
39.4%
77.3%
Q4 24
42.0%
78.1%
Q3 24
40.2%
77.4%
Q2 24
77.5%
Q1 24
50.8%
76.8%
Operating Margin
BIOX
BIOX
SPT
SPT
Q4 25
-9.0%
Q3 25
9.3%
-7.9%
Q2 25
-11.0%
Q1 25
1.5%
-10.2%
Q4 24
14.5%
-12.8%
Q3 24
2.5%
-16.4%
Q2 24
-16.6%
Q1 24
15.7%
-13.7%
Net Margin
BIOX
BIOX
SPT
SPT
Q4 25
Q3 25
-9.6%
-8.1%
Q2 25
-10.7%
Q1 25
-2.6%
-10.3%
Q4 24
0.6%
Q3 24
-6.6%
-16.6%
Q2 24
-17.0%
Q1 24
11.6%
-14.0%
EPS (diluted)
BIOX
BIOX
SPT
SPT
Q4 25
$-0.18
Q3 25
$-0.12
$-0.16
Q2 25
$-0.21
Q1 25
$-0.02
$-0.19
Q4 24
$0.00
$-0.25
Q3 24
$-0.10
$-0.30
Q2 24
$-0.30
Q1 24
$0.14
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
SPT
SPT
Cash + ST InvestmentsLiquidity on hand
$15.5M
$95.3M
Total DebtLower is stronger
$40.0M
Stockholders' EquityBook value
$288.3M
$203.4M
Total Assets
$734.9M
$523.1M
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
SPT
SPT
Q4 25
$95.3M
Q3 25
$15.5M
$90.6M
Q2 25
$101.5M
Q1 25
$38.5M
$100.9M
Q4 24
$29.2M
$86.4M
Q3 24
$32.3M
$82.9M
Q2 24
$80.9M
Q1 24
$16.4M
$69.2M
Total Debt
BIOX
BIOX
SPT
SPT
Q4 25
$40.0M
Q3 25
Q2 25
Q1 25
Q4 24
$25.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BIOX
BIOX
SPT
SPT
Q4 25
$203.4M
Q3 25
$288.3M
$194.1M
Q2 25
$184.6M
Q1 25
$345.0M
$175.3M
Q4 24
$346.3M
$166.6M
Q3 24
$346.0M
$158.1M
Q2 24
$152.1M
Q1 24
$348.5M
$147.3M
Total Assets
BIOX
BIOX
SPT
SPT
Q4 25
$523.1M
Q3 25
$734.9M
$481.4M
Q2 25
$422.9M
Q1 25
$798.2M
$424.7M
Q4 24
$835.2M
$428.3M
Q3 24
$827.3M
$388.8M
Q2 24
$393.6M
Q1 24
$836.1M
$389.9M
Debt / Equity
BIOX
BIOX
SPT
SPT
Q4 25
0.20×
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
SPT
SPT
Operating Cash FlowLast quarter
$14.4M
$10.9M
Free Cash FlowOCF − Capex
$9.9M
FCF MarginFCF / Revenue
8.2%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$39.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
SPT
SPT
Q4 25
$10.9M
Q3 25
$14.4M
$9.3M
Q2 25
$5.1M
Q1 25
$23.3M
$18.1M
Q4 24
$-5.4M
$4.1M
Q3 24
$5.2M
$9.0M
Q2 24
$2.1M
Q1 24
$-17.4M
$11.2M
Free Cash Flow
BIOX
BIOX
SPT
SPT
Q4 25
$9.9M
Q3 25
$8.5M
Q2 25
$4.2M
Q1 25
$16.7M
Q4 24
$3.3M
Q3 24
$8.5M
Q2 24
$1.6M
Q1 24
$10.1M
FCF Margin
BIOX
BIOX
SPT
SPT
Q4 25
8.2%
Q3 25
7.4%
Q2 25
3.7%
Q1 25
15.3%
Q4 24
3.0%
Q3 24
8.3%
Q2 24
1.6%
Q1 24
10.4%
Capex Intensity
BIOX
BIOX
SPT
SPT
Q4 25
0.9%
Q3 25
0.7%
Q2 25
0.8%
Q1 25
1.2%
Q4 24
0.8%
Q3 24
0.5%
Q2 24
0.5%
Q1 24
1.1%
Cash Conversion
BIOX
BIOX
SPT
SPT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons